Pegfilgrastim

From WikiProjectMed
Jump to navigation Jump to search
Pegfilgrastim
Names
Trade namesNeulasta, Udenyca, Ristempa, others[1]
Other namespegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, pegfilgrastim-jmdb
  • N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene)
Clinical data
Drug classGranulocyte colony-stimulating factor (GCSF)[2]
Main usesLow neutrophils due to chemotherapy[3]
Side effectsBone pain, splenic rupture, adult respiratory distress syndrome (ADRS), anaphylaxis[4][3]
Pregnancy
category
Routes of
use
Subcutaneous
Typical dose6 mg[4]
External links
AHFS/Drugs.comMonograph
US NLMPegfilgrastim
MedlinePlusa607058
Legal
License data
Legal status
Pharmacokinetics
Elimination half-life15–80 hrs
Chemical and physical data
FormulaC845H1343N223O243S9
Molar mass18802.90 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Pegfilgrastim, sold under the brand name Neulasta among others, is a medication used treat low neutrophils in those on chemotherapy or with radiation sickness.[3][2] Its benefits are similar to filgrastim but does not need to be given as often.[3] It is given by injection under the skin.[4]

Common side effects include bone pain.[4] Other side effects may include splenic rupture, adult respiratory distress syndrome (ADRS), and anaphylaxis.[3] It is a PEGylated form of filgrastim, a recombinant granulocyte colony-stimulating factor (GCSF).[2] It increases the production of white blood cells (leucocytes) by the bone marrow.[4]

Pegfilgrastim was approved for medical use in the United States, Europe, and Australia in 2002.[3][4][9] In the United States it costs about 6,200 USD per dose as of 2021; though a biosimilar is available at 3,800 USD per dose.[10][11] In the United Kingdom this amount costs the NHS about £410.[12]

Medical uses

Pegfilgrastim is used to decrease the incidence of infection, as manifested by febrile neutropenia, in people with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia; and to increase survival in people acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome).[2][13][14]

Dosage

It is given as a 6 mg injection.[4] Two doses one week apart may be used in those with radiation sickness.[2]

Chemistry

Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).[15][3]

Society and culture

Pegfilgrastim was originally developed by Amgen.[16]

Biosimilars

Ristempa was approved for medical use in Australia in January 2017.[17]

Tezmota was approved for medical use in Australia in March 2018.[18]

Pegfilgrastim-jmdb (Fulphila) was approved for medical use in the United States in June 2018.[19][20]

Fulphila was approved for medical use in Australia in August 2018.[21]

Pelgraz was approved for medical use in the European Union in September 2018.[22]

Udenyca was approved for medical use in the European Union in September 2018.[23]

On November 2, 2018, Coherus Biosciences received FDA approval for its biosimilar, pegfilgrastim-cbqv (Udenyca). The push to receive approval and begin production of Udenyca was due in large part to the quickly increasing cost of Neulasta, which has nearly tripled since its release in 2002.[24][25]

Pelmeg was approved for medical use in the European Union in November 2018.[26]

Fulphila was approved for medical use in the European Union in November 2018.[27]

Ziextenzo was approved for medical use in the European Union in November 2018.[28]

Grasustek was approved for medical use in the European Union in June 2019.[29]

Ziextenzo was approved for medical use in Australia in July 2019.[5]

Pelgraz was approved for medical use in Australia in August 2019.[30]

Neutropeg was approved for medical use in Australia in August 2019.[31]

Pegfilgrastim-bmez (Ziextenzo) was approved for medical use in the United States in November 2019.[32][33]

Cegfila was approved for medical use in the European Union in December 2019.[34]

Pegfilgrastim-apgf (Nyvepria) was approved for medical use in the United States in June 2020.[35] On 17 September 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for Nyvepria.[36] The applicant for this medicinal product is Pfizer Europe MA EEIG.[36] Nyvepria was approved for medical use in the European Union in November 2020.[37]

References

  1. Drugs.com International brand names for pegfilgrastim Page accessed April 1, 2016
  2. 2.0 2.1 2.2 2.3 2.4 2.5 "Neulasta- pegfilgrastim kit Neulasta- pegfilgrastim injection". DailyMed. Retrieved 14 July 2021.
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 "Pegfilgrastim Monograph for Professionals". Drugs.com. 22 August 2019. Retrieved 11 June 2020.
  4. 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 "Neulasta EPAR". European Medicines Agency (EMA). Retrieved 2 April 2020.
  5. 5.0 5.1 5.2 "Ziextenzo". Therapeutic Goods Administration (TGA). 13 December 2019. Retrieved 25 August 2020.
  6. "Pegfilgrastim Use During Pregnancy". Drugs.com. 9 December 2019. Retrieved 13 July 2020.
  7. "Neulasta Pre-Filled Syringe - Summary of Product Characteristics (SmPC)". (emc). 1 June 2021. Retrieved 11 October 2021.
  8. "Neulasta On Body Injector - Summary of Product Characteristics (SmPC)". (emc). Retrieved 11 October 2021.
  9. "NEULASTA pegfilgrastim rbe 6mg/0.6mL injection syringe with stelmi needle shield". Retrieved 27 October 2021.
  10. "Pegfilgrastim Prices, Coupons & Savings Tips - GoodRx". GoodRx.
  11. "Pegfilgrastim-Bmez Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 27 October 2021.
  12. BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1078. ISBN 978-0857114105.
  13. Cerchione C, Catalano L, Peluso I, Nappi D, Di Perna M, Salvatore D, et al. (December 2016). "Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone". Supportive Care in Cancer. 24 (12): 4835–4837. doi:10.1007/s00520-016-3430-9. PMC 5082581. PMID 27726031.
  14. Parker SD, King N, Jacobs TF (November 2020). "Pegfilgrastim". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
  15. Ho, Rodney J. Y.; Gibaldi, Milo, eds. (2004). "Pegfilgrastim". Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs. John Wiley & Sons. pp. 157–159. ISBN 978-0-471-45027-6.
  16. "Drug Approval Package: Neulasta (Pegfilgrastim) NDA #125031". U.S. Food and Drug Administration (FDA). 25 October 2004. Retrieved 11 June 2020.
  17. https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=DFB942E54351D3EDCA2585880030EB48&agid=(PrintDetailsPublic)&actionid=1
  18. https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=86E9A09F47791A95CA2585880030EB4A&agid=(PrintDetailsPublic)&actionid=1
  19. "FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment". U.S. Food and Drug Administration (Press release). 4 June 2018. Retrieved 11 June 2020.
  20. "Drug Approval Package: Fulphila". U.S. Food and Drug Administration (FDA). 26 October 2018. Retrieved 11 June 2020.
  21. https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=FB6888358ED3FA79CA25859D00425423&agid=(PrintDetailsPublic)&actionid=1
  22. "Pelgraz EPAR". European Medicines Agency (EMA). Retrieved 2 April 2020.
  23. "Udenyca EPAR". European Medicines Agency (EMA). Retrieved 2 April 2020.
  24. "FDA Approves Coherus' Pegfilgrastim Biosimilar, Udenyca".
  25. "Drug Approval Package: Udenyca". U.S. Food and Drug Administration (FDA). 5 March 2019. Retrieved 11 June 2020.
  26. "Pelmeg EPAR". European Medicines Agency (EMA). Retrieved 2 April 2020.
  27. "Fulphila EPAR". European Medicines Agency (EMA). Retrieved 2 April 2020.
  28. "Ziextenzo EPAR". European Medicines Agency (EMA). Retrieved 2 April 2020.
  29. "Grasustek EPAR". European Medicines Agency (EMA). Retrieved 2 April 2020.
  30. https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=D9374DDB59026212CA2585CE004233D0&agid=(PrintDetailsPublic)&actionid=1
  31. https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=C31CEBE1997897ABCA2585CE004233CE&agid=(PrintDetailsPublic)&actionid=1
  32. "Ziextenzo". U.S. Food and Drug Administration (FDA). Retrieved 17 December 2019.
  33. "Drug Approval Package: Ziextenzo". U.S. Food and Drug Administration (FDA). 27 December 2019. Retrieved 11 June 2020.
  34. "Cegfila EPAR". European Medicines Agency (EMA). Retrieved 2 April 2020.
  35. "Nyvepria". U.S. Food and Drug Administration (FDA). Retrieved 11 June 2020.
  36. 36.0 36.1 "Nyvepria: Pending EC decision". European Medicines Agency (EMA). 18 September 2020. Retrieved 21 September 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  37. "Nyvepria EPAR". European Medicines Agency (EMA). Retrieved 11 October 2021.

External links

External sites:
Identifiers: